Shares of TG Therapeutics Inc (NASDAQ:TGTX) have received a consensus rating of “Buy” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $12.30.
TGTX has been the topic of a number of research analyst reports. BidaskClub cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. B. Riley initiated coverage on shares of TG Therapeutics in a research note on Tuesday, January 8th. They issued a “buy” rating and a $10.00 price target on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $8.00 price target on shares of TG Therapeutics in a research note on Wednesday, February 6th. Zacks Investment Research cut shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Finally, HC Wainwright reissued a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, January 22nd.
Get TG Therapeutics alerts:In other TG Therapeutics news, CFO Sean A. Power sold 37,275 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $4.13, for a total value of $153,945.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 15.10% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its holdings in shares of TG Therapeutics by 1,891.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 18,425 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 17,500 shares during the period. Highland Capital Management LP raised its holdings in shares of TG Therapeutics by 60.5% during the 3rd quarter. Highland Capital Management LP now owns 753,151 shares of the biopharmaceutical company’s stock worth $4,218,000 after acquiring an additional 283,910 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of TG Therapeutics during the 4th quarter worth $642,000. Northern Trust Corp raised its holdings in shares of TG Therapeutics by 19.3% during the 2nd quarter. Northern Trust Corp now owns 751,725 shares of the biopharmaceutical company’s stock worth $9,885,000 after acquiring an additional 121,424 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of TG Therapeutics during the 3rd quarter worth $1,974,000. Institutional investors own 57.47% of the company’s stock.
TG Therapeutics stock traded up $0.01 during trading on Tuesday, reaching $4.53. The company had a trading volume of 1,580,749 shares, compared to its average volume of 1,428,787. TG Therapeutics has a 1-year low of $3.32 and a 1-year high of $17.35. The stock has a market capitalization of $375.25 million, a P/E ratio of -2.37 and a beta of 2.07.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Friday, November 9th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.12. TG Therapeutics had a negative net margin of 99,001.33% and a negative return on equity of 185.20%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. On average, sell-side analysts predict that TG Therapeutics will post -2.03 EPS for the current fiscal year.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Featured Article: Compound Interest
No comments:
Post a Comment